TY - JOUR
T1 - Interleukin 21, interleukin 23, and transforming growth factor β1 in HLA-A29-associated birdshot retinochoroidopathy
AU - Yang, Paul
AU - Foster, C. Stephen
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Foster is a paid consultant for Abbott, Alcon Laboratories, Allergan, Ista Pharmaceuticals, LUX Biosciences, Novartis Pharmaceutical, and Bausch & Lomb Surgical. He has grant support from Abbott , Alcon Laboratories , Allergan , Eyegate , LUX Biosciences , and Novartis Pharmaceutical . He is a paid speaker for Alcon Laboratories, Allergan, Inspire, Ista Pharmaceuticals, and LUX Biosciences. The authors indicate no funding support for this study. Contributions of authors: design and conduct of the study (C.S.F., P.Y.); collection, management, analysis, and interpretation of the data (C.S.F., P.Y.); and preparation, review, and approval of the manuscript (C.S.F., P.Y.).
PY - 2013/8
Y1 - 2013/8
N2 - Purpose: To determine the peripheral levels of 20 immune mediators in serum samples from patients with birdshot retinochoroidopathy (BSRC). Design: Single-center prospective case-control study. Methods: The serum of 17 BSRC patients during different phases of disease activity and therapy were analyzed with a quantitative multiplex sandwich enzyme-linked immunosorbent assay-based microarray to determine the levels of 20 immune mediators (T cell and proinflammatory). The serum of 12 healthy volunteers was used as controls. Results: Serum levels of interleukin (IL)-21 (P =.0005), IL-23 (P =.0005), and transforming growth factor (TGF)-β1 (P =.0011) were elevated in BSRC patients with active disease naïve to systemic therapy compared with that of controls. There was no significant difference in the serum levels of immune mediators between controls and BSRC patients who had a current or past history of IMT or who were in remission. The levels of IL-21, IL-23, and TGF-β1 were positively correlated (IL-23/IL-21, r = 0.91; TGF-β1/IL-21, r = 0.97; TGF-β1/IL-23, r = 0.87; for all, P <.0001). Conclusions: BSRC patients with active disease naïve to systemic therapy have elevated serum levels of 3 key immune mediators known to promote T helper 17 (Th17) cells in autoimmune disease. Our results suggest that IL-21, IL-23, and TGF-β1 may play an important role in the development of site-specific Th17 cell-mediated inflammation in BSRC, which underscore the importance of systemic therapy and offer new insights into the potential of targeted treatments.
AB - Purpose: To determine the peripheral levels of 20 immune mediators in serum samples from patients with birdshot retinochoroidopathy (BSRC). Design: Single-center prospective case-control study. Methods: The serum of 17 BSRC patients during different phases of disease activity and therapy were analyzed with a quantitative multiplex sandwich enzyme-linked immunosorbent assay-based microarray to determine the levels of 20 immune mediators (T cell and proinflammatory). The serum of 12 healthy volunteers was used as controls. Results: Serum levels of interleukin (IL)-21 (P =.0005), IL-23 (P =.0005), and transforming growth factor (TGF)-β1 (P =.0011) were elevated in BSRC patients with active disease naïve to systemic therapy compared with that of controls. There was no significant difference in the serum levels of immune mediators between controls and BSRC patients who had a current or past history of IMT or who were in remission. The levels of IL-21, IL-23, and TGF-β1 were positively correlated (IL-23/IL-21, r = 0.91; TGF-β1/IL-21, r = 0.97; TGF-β1/IL-23, r = 0.87; for all, P <.0001). Conclusions: BSRC patients with active disease naïve to systemic therapy have elevated serum levels of 3 key immune mediators known to promote T helper 17 (Th17) cells in autoimmune disease. Our results suggest that IL-21, IL-23, and TGF-β1 may play an important role in the development of site-specific Th17 cell-mediated inflammation in BSRC, which underscore the importance of systemic therapy and offer new insights into the potential of targeted treatments.
UR - http://www.scopus.com/inward/record.url?scp=84880572235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880572235&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2013.03.004
DO - 10.1016/j.ajo.2013.03.004
M3 - Article
C2 - 23622563
AN - SCOPUS:84880572235
SN - 0002-9394
VL - 156
SP - 400-406.e2
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 2
ER -